Fig. 1

Patient outcomes after RT for medulloblastoma with residual or dissimilated diseases. The prtPFS for patients achieved CR and non-CR after RT (A), metastatic status at diagnosis (B), residual disease site before RT (C) and histological subtype (D). The prtOS for patients achieved CR and non-CR after RT (E), metastatic status at diagnosis (F), residual disease site before RT (G) and histological subtype (H)